Please assess the completion status of the following clinical trial:

Trial Title: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) \> 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory~* Last IV bisphosphonate treatment must be \>/= to 7 days and \</= to 30 days before the screening corrected serum calcium~* Adults (\>/=18 years)~* Adequate organ function as defined by the following criteria:~* serum aspartate aminotransferase (AST) \</= 5 x upper limit of normal (ULN)~* serum alanine aminotransferase (ALT) \</= 5 x upper limit of normal~* serum total bilirubin \</= 2 x upper limit of normal~Exclusion Criteria:~* Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease~* Receiving dialysis for renal failure~* Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC~* Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC~* Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study~* Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)~* Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment~* Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment~* Subject will not be available for follow-up assessment.~* Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- denosumab (Type: EXPERIMENTAL): Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).